ClinicalTrials.gg
RecruitingNCT05303519SIGMAUpdated Nov 17, 2026

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

A Phase 3 interventional study of safusidenib and Placebo in Glioma, Astrocytoma, Grade IV and IDH1-mutant Glioma, sponsored by Nuvation Bio Inc.. Recruiting at 75 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nuvation Bio Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Nov 17, 2026First sites in 6 new countriesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Planned enrollment
9th of 737
365 · median 30
Started
2023
with 34 others
Phase 3
20 of 851
3 open now
Primary completion
2028-12
later than 185 of 228 live
Registered
693rd of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 9th largest by planned enrollment of the 737 interventional ones that give a count, is one of 35 that started in 2023, is one of 20 in phase 3, reaches primary completion later than 185 of the 228 other live ones, and was the 693rd registered.

Glioma

1,454 studies on the registry are indexed under Glioma; 350 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.

The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled.

The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

Read the detailed description

Part 1 of this study will enroll up to 25 patients that will be randomized 1:1:1:1:1 (5 patients per group) to receive one of the daily oral doses of safusidenib at 125 mg twice a day (BID), 250 mg BID, 500 mg once daily (QD), 375 mg BID, or 500 mg BID. The PK characteristics and safety and initial efficacy data will be assessed in Part 1.

Part 1 was fully enrolled as of 19 Dec 2023 and participants are currently ongoing.

Part 2 will include approximately 300 participants with IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Participants will be randomized (1:1) after their last dose of adjuvant temozolomide to receive either oral safusidenib 250 mg BID or placebo in 28-day continuous cycles. Patients will continue treatment until progression of disease or until other discontinuation criteria are met. The tumor response evaluation will be conducted on a regular basis until progression of disease per Blinded Independent Central Review (BICR), consent withdrawal, or death, whichever occurs first. Long-term survival follow-up will be conducted as well.

Part 3 will include approximately 40 participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma with measurable disease who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy. Participants will receive oral safusidenib 250 mg BID in 28-day continuous cycles until disease progression or another reason for discontinuation occurs.

03

Conditions studied

  • Glioma
  • Astrocytoma, Grade IV
  • IDH1-mutant Glioma
  • Astrocytoma, IDH-Mutant, Grade 3
  • Astrocytoma, IDH-Mutant, Grade 4
  • Astrocytoma, IDH-Mutant, Grade 2
  • Oligodendroglioma
  • Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Keywords

  • safusidenib
  • IDH1-mutant glioma
  • astrocytoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Part 1:

  1. Patient must be ≥ 18 years of age at the time of signing the form (ICF).
  2. Patient must have confirmed recurrent or progressive WHO Grade 2 glioma or Grade 3 glioma with IDH1 R132H or R132C mutation confirmed by immunohistochemistry or molecular genetic testing.
  3. The IDH mutation, and other applicable gene/molecular alterations (see Table 10-2) are determined by a validated assay as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified/College of American Pathologists (CAP)-accredited or locally equivalent clinical laboratories. Prior clinical pathology report fulfilling the diagnosis criteria prior to screening with tumor samples collected is acceptable for patient enrollment in both Part 1 and Part 2.
  4. Patient has received no more than 2 prior therapies for disease recurrence/progression.
  5. Patient has disease recurrence or progression or cannot tolerate the most recent therapy.
  6. Patient must have a (s) as per the RANO-HGG criteria for primarily enhancing lesions or RANO-LGG criteria for primarily non-enhancing lesions. The lesion (s) must be visible on 2 or more axial slices and have perpendicular diameters of at least 10 × 10 mm. The definition of primarily enhancing lesions or primarily non-enhancing lesions is referred to Section 8.3.1.

Key Inclusion Criteria for Part 2 and 3:

  1. Must be ≥18 years old at the time of signing the ICF.
  2. Must agree to submit sufficient tumor tissue for retrospective biomarker and histological analyses. This requirement may be waived in rare circumstances with approval by the Sponsor.
  3. Has adequate hematologic and organ function

Key Inclusion Criteria for Part 2:

  1. Diagnosis of histologically confirmed IDH1-mutant Grade 2, Grade 3 with high risk features or Grade 4 astrocytoma, per WHO 2021 classification and Investigator Assessment.
  2. Have an IDH1 mutation (R132H/C/G/S/L) based on IHC (R132H only), polymerase chain reaction (PCR), or next-generation sequencing (NGS). CDKN2A/B status and at least 1 of the following must be confirmed: absence of 1p19q co-deletion by fluorescence in situ hybridization, array comparative genomic hybridization, or NGS; presence of an ATRX loss of function mutation by NGS; or loss of normal ATRX expression by IHC. A validated assay performed in a CLIA-certified/CAP-accredited (or local equivalent) clinical laboratory must be used for all of the aforementioned results. Documentation of biomarker status, including redacted molecular pathology and NGS reports, must be provided during Screening.
  3. Must not have experienced tumor recurrence or progression between first day of radiotherapy and randomization by local assessment per RANO 2.0.
  4. Participants must have completed radiation therapy with a minimum of 80% of planned treatment completed (with or without concurrent temozolomide) and between 6 and 12 cycles of adjuvant . Randomization must occur at least 28 days and not more than 75 days after the final dose of temozolomide.

Key Inclusion Criteria for Part 3:

  1. Have had at least 1 prior surgery for glioma (, sub-total resection, or gross total resection), with the most recent surgery having occurred at least 90 days and no longer than 5 years before the date of enrollment, have not had any other prior anticancer therapy, including chemotherapy and radiotherapy, and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator.
  2. Have histologically confirmed Grade 3 IDH-mutant oligodendroglioma according to WHO 2021 criteria per local assessment.
  3. Have residual or recurrent measurable disease per RANO 2.0 and confirmed by BICR, at the time of enrollment.
  4. Have an IDH1 mutation (R132H/C/G/S/L). The presence of 1p19q co-deletion must also be confirmed. All results must be generated using a validated assay performed in a CLIA-certified/CAP-accredited (or local equivalent) clinical laboratory.

Key Exclusion Criteria for Part 1:

  1. Prior anti-cancer therapy, within the applicable periods shown below, before the start of the protocol treatment:
  2. Systemic drug therapies: within 3 weeks (lomustine within 6 weeks)
  3. Surgery: within 3 weeks
  4. Radiation therapy: within 12 weeks
  5. agents: within 5 half-lives for other investigational agents
  6. Patient did receive the prior therapy targeted to IDH1 mutation..
  7. Known to safusidenib or to any drug with similar chemical structure or to any other present in the pharmaceutical form of safusidenib.

Key Exclusion Criteria for Part 2 and 3:

  1. Participants with prior or anticipated treatment with anti-angiogenic agents such as Avastin (bevacizumab), agents known to target IDH1 or IDH2, or investigational agents for glioma are excluded.
  2. Have brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
  3. Significant functional or neurocognitive deficits, including uncontrolled seizures, that would preclude participation in protocol-defined study activities, as assessed by Investigator.
  4. Evidence of diffuse .
  5. History of significant cardiac disease within 12 months prior to randomization (if applicable) or first dose of study drug (if randomization does not apply).
  6. If taking , must be on a stable or decreasing dose for the 14 days prior to randomization (if applicable) or first dose of study drug (if randomization does not apply).
  7. Participants with other must have received curative treatment and been disease-free for at least 3 years. Curatively resected skin cancer or curatively treated carcinoma in situ is allowed.
  8. Have a condition that would interfere with, or increase the risk of, study participation.

Key Exclusion Criteria for Part 2 1. Participants may not have received any anticancer treatments other than surgery, radiation, concurrent/adjuvant temozolomide, and tumor-treating fields. Tumor-treating fields must be discontinued prior to randomization.

Key Exclusion Criteria for Part 3:

1. Participants may not have received any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) for treatment of glioma, including radiotherapy.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
365 participants (estimated)

Study arms

  • Experimental
    safusidenib 125mg bid (part 1)

    safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.

    Drug: safusidenib

  • Experimental
    safusidenib 250mg bid (part 1)

    safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.

    Drug: safusidenib

  • Experimental
    safusidenib 500mg qd (part 1)

    safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.

    Drug: safusidenib

  • Experimental
    safusidenib 375mg bid (part 1)

    safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.

    Drug: safusidenib

  • Experimental
    safusidenib 500mg bid (part 1)

    safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.

    Drug: safusidenib

  • Experimental
    safusidenib 250mg bid (Part 2)

    safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs.

    Drug: safusidenib

  • Placebo comparator
    placebo (Part 2)

    Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.

    Drug: Placebo

  • Experimental
    safusidenib 250mg bid (Part 3)

    safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs.

    Drug: safusidenib

Interventions

  • safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.

    Also known as: DS-1001b, AB-218

  • DrugPlacebo

    Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)

    calculate Percentage and numbers of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed by CTCAE 5.0

    Time frame: From participants sign ICF to 30 days after last dose,average 2 years

  2. Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0

    PFS is defined as the time from randomization to the date of the first documented disease progression assessed by BICR per RANO 2.0 or death (by any cause in the absence of disease progression).

    Time frame: From randomization until the date of first documented disease progression, average 2 years

  3. Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

Secondary outcomes

  1. Part 1: Cmax of safusidenib

    Peak Plasma Concentration (Cmax)

    Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)

  2. Part 1: Tmax of safusidenib

    the time for safusidenib to reach Cmax

    Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)

  3. Part 1: AUC8h of safusidenib

    Area under the plasma concentration curve (AUC) from time 0 to 8 hours

    Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)

  4. Part 1 : AUC12h of safusidenib

    Area under the plasma concentration curve (AUC) from time 0 to 12 hours

    Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)

  5. Part 1: AUC24h [QD only] of safusidenib

    Area under the plasma concentration curve (AUC) from time 0 to 24h hours for 500mg qd cohort

    Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)

  6. Part 1 : Ctrough of safusidenib

    Lowest plasma concentration reached after AB-218 administration

    Time frame: on Days 2, 3, 4, 6, 8, 9 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 6 and 8 (every cycle is 28 days)

  7. Part 1: Overall Response Rate (ORR) assessed by the investigator

    ORR (defined as the proportion of participants with the best overall confirmed response of Complete Response (CR), Partial Response (PR) or Minor Response (MR)\[for RANO-HGG/RANO LGG\] according to the appropriate tumor response criteria) as assessed by the Investigator

    Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years

  8. Part 1: Duration of Response (DOR) assessed by the Investigator

    DOR, defined as the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression per RANO-HGG/RANO-LGG as applicable, or death (by any cause in the absence of progression), for participants with confirmed objective response, as assessed by the Investigator

    Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years

  9. Part 1: Disease control rate (DCR) assessed by the Investigator

    DCR, defined as the proportion of patients with a best overall response of CR, PR, Stable Disease (SD), or Minor Response (MR) per RANO-HGG/RANO-LGG as applicable, as assessed by the Investigator

    Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years

  10. Part 1: Progression free survival (PFS) assessed by the Investigator

    PFS, defined as the time from the first dose of study drug to the date of the first documented disease progression per RANO-HGG/RANO-LGG as applicable, or death (by any cause in the absence of disease progression), as assessed by the Investigator

    Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years

  11. Part1: Time to Response (TTR) assessed by the Investigator.

    TTR, the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per RANO-HGG/RANO-LGG as applicable, for participants with confirmed objective response, as assessed by the Investigator.

    Time frame: From the first dose of study drug until the date of first documented objective response, average 2 years

  12. Part 1: Overall Survival (OS)

    OS, defined as the time from randomization to death from any cause. Participants without death information at the analysis cutoff date will be censored at last date known to be alive.

    Time frame: from the first dose of study drug to date of death, average 7 years

  13. Part 2: Overall Survival (OS)

    OS, defined as the time from randomization to death from any cause.

    Time frame: from randomization to date of death, average 7 years

  14. Part 2: PFS assessed by the Investigator.

    PFS, defined as the time from randomization to the date of the first documented disease progression per RANO 2.0, or death (by any cause in the absence of disease progression), as assessed by the Investigator.

    Time frame: from randomization until the date of first documented disease progression, average 2 years

  15. Part2: Time to Next Intervention (TTNI) by Investigator assessment

    TTNI, defined as the time from randomization to initiation of the first new anticancer therapy, or death due to any cause, whichever comes earlier. Participants who neither initiated new anticancer therapy nor have died at the analysis cutoff date will be censored at the last date known to be alive.

    Time frame: From randomization until the date of next treatment, average 2 years

  16. Part2: DCR assessed by BICR and by the Investigator

    DCR, defined as the proportion of participants with a best overall response of CR, PR, MR, or SD per RANO 2.0, as assessed by the Investigator and BICR

    Time frame: from randomization until the date of first documented disease progression, average 2 years

  17. Part2: ORR

    ORR, defined as the proportion of participants with the confirmed best overall response of CR, PR, or MR per RANO 2.0, as assessed by BICR and the Investigator.

    Time frame: from randomization until the date of first documented disease progression, average 2 years

  18. Part2: DOR, assessed by BICR and the Investigator

    DOR, the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression RANO 2.0, or death (by any cause in the absence of progression), for participants with confirmed objective response, as assessed by the BICR and the Investigator.

    Time frame: from randomization until the date of first documented disease progression, average 2 years

  19. Part2: Time to Response (TTR) assessed by BICR and by the Investigator

    TTR, defined as the time from randomization to the first documentation of objective response (CR, PR, or MR) per RANO 2.0, for participants with confirmed objective response, as assessed by the BICR and the Investigator.

    Time frame: From randomization until the date of first documented objective response, average 2 years

  20. Part2: Health-related quality of life

    The Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire

    Time frame: From the first dose of study drug to treatment discontinuation, average 2 years

  21. Part2: Safety and tolerability

    AEs graded by NCI CTCAE v5.0, laboratory abnormalities as graded by NCI CTCAE v5.0, vital signs, physical examinations, and ECGs.

    Time frame: from the first dose of study drug until 30 days after treatment discontinuation, average 2 years

  22. Part2: Seizure Activity

    Defined as seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications.

    Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years

  23. Part2: Safusidenib PK Profile

    Defined as safusidenib concentrations and PK parameters.

    Time frame: from the first dose of study drug through 20 weeks

  24. Part 3: ORR, assessed by the Investigator

    ORR, defined as the proportion of participants with the confirmed best overall response of CR, PR, or MR per RANO 2.0, as assessed by the Investigator.

    Time frame: From first dose of study drug until the date of first documented disease progression, average 18 months

  25. Part 3: DOR, assessed by BICR and the Investigator

    DOR, the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression per RANO 2.0, or death (by any cause in the absence of progression), as assessed by the BICR and the Investigator.

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

  26. Part 3: Time to Next Intervention (TTNI)

    TTNI, defined as the time from the first dose of study drug to initiation of the first subsequent anticancer therapy.

    Time frame: From the first dose of study drug until the date of next treatment, average 18 months

  27. Part 3: PFS assessed by BICR and the Investigator.

    PFS, defined as the time from the first dose of study drug to the date of the first documented disease progression per RANO 2.0, or death (by any cause in the absence of disease progression), as assessed by BICR and the Investigator.

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

  28. Part 3: DCR assessed by BICR and by the Investigator

    DCR, defined as the proportion of participants with a best overall response of CR, PR, MR, or SD per RANO 2.0, as assessed by the Investigator and BICR

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

  29. Part 3: Time to Response (TTR) assessed by BICR and by the Investigator

    TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per RANO 2.0, as assessed by the BICR and the Investigator.

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

  30. Part 3: Overall Survival (OS)

    OS, defined as the time from the first dose of study drug to death from any cause.

    Time frame: From the first dose of study drug until the date of death, average 7 years

  31. Part 3: Safety and tolerability

    AEs graded by NCI CTCAE v5.0, laboratory abnormalities as graded by NCI CTCAE v5.0, vital signs, physical examinations, and ECGs.

    Time frame: From the first dose of study drug until 30 days after treatment discontinuation, average 18 months

  32. Part 3: Safusidenib PK Profile

    Defined as safusidenib concentrations and PK parameters.\[Time Frame: from the first dose of study drug through 20 weeks\]

    Time frame: From the first dose of study drug through 20 weeks

  33. Part 3: Health-related quality of life

    The Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Quality of Life in Epilepsy (QOLIE-10-P) questionnaires.

    Time frame: From the first dose of study drug to treatment discontinuation, average 18 months

  34. Part 3: Seizure Activity

    Defined as seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications.

    Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months

07

Study locations

61 of 75 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Dec 2028, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2022
First posted
Mar 31, 2022
StartActual
Jun 5, 2023
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed — first sites in France, Germany, Italy, Spain, Sweden and 1 more
All 6 countries

France, Germany, Italy, Spain, Sweden, United Kingdom

. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United StatesNot yet recruiting→Recruiting
Show 15 added (3 United States, 2 France, 2 Germany, 2 Italy, 2 Spain, 2 Sweden, 1 Australia, 1 United Kingdom)
  • Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center · Chicago, United States
  • University of Minnesota · Minneapolis, United States
  • OneOncology Research Network · Nashville, United States
  • Sir Charles Gairdner Hospital · Nedlands, Australia
  • Hospices Civils de Lyon - Departement Neurologie Pierre Wertheimer · Lyon, France
  • Hôpitaux Universitaires Pitié Salpêtrière · Paris, France
  • Universitaetsklinikum Bonn - Klinik und Poliklinik fuer Neurologie · Bonn, Germany
  • St. Marien Hospital Lünen · Lünen, Germany
  • Gruppo Humanitas-Humanitas Research Hospital - Cancer Center · Rozzano, Italy
  • Istituto Oncologico Veneto (IOV) - IRCCS · Padova, Italy
  • Vall d'Hebron Institut d'Oncologia (VHIO) · Barcelona, Spain
  • Hospital Universitario 12 de Octubre (H12O) · Madrid, Spain
  • Sahlgrenska University Hospital · Gothenburg, Sweden
  • Karolinska University Hospital · Solna, Sweden
  • Royal Marsden Hospital · London, United Kingdom
Show 1 removed
  • Sir Charles Gairdner Hospital · Nedlands, Australia
across 2 updates, Oct 19, 2026 – Nov 17, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • Mayo Clinic - Arizona · Phoenix, United StatesContact m•••@mayo.edu · •••8227→m•••@mayo.edu · •••0015
  • Mayo Clinic - Florida · Jacksonville, United StatesContact m•••@mayo.edu · •••0856→m•••@mayo.edu · •••0015
  • Mayo Clinic - Rochester · Rochester, United StatesContact m•••@mayo.edu · •••3564→m•••@mayo.edu · •••0015
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact R•••@mskcc.org→y•••@mskcc.org · •••0840Contact •••3051→•••0538
  • Henry Ford Hospital · Detroit, United StatesContact p•••@hfhs.org · •••1606→k•••@hfhs.org · •••7859
  • Rutgers Cancer Institute · New Brunswick, United StatesContact person changed (no phone or email listed)
  • Columbia University Medical Center · New York, United StatesContact person changed (no phone or email listed)
  • University of Texas Southwestern Medical Center · Dallas, United StatesContact person changed (no phone or email listed)
  • Royal North Shore Hospital · Saint Leonards, AustraliaContact person changed (no phone or email listed)
across 2 updates, Oct 19, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    15 sites added, 1 site removed — first sites in France, Germany, Italy, Spain, Sweden and 1 more
    All 6 countries

    France, Germany, Italy, Spain, Sweden, United Kingdom

    Show 15 added (3 United States, 2 France, 2 Germany, 2 Italy, 2 Spain, 2 Sweden, 1 Australia, 1 United Kingdom)
    • Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center · Chicago, United States
    • University of Minnesota · Minneapolis, United States
    • OneOncology Research Network · Nashville, United States
    • Sir Charles Gairdner Hospital · Nedlands, Australia
    • Hospices Civils de Lyon - Departement Neurologie Pierre Wertheimer · Lyon, France
    • Hôpitaux Universitaires Pitié Salpêtrière · Paris, France
    • Universitaetsklinikum Bonn - Klinik und Poliklinik fuer Neurologie · Bonn, Germany
    • St. Marien Hospital Lünen · Lünen, Germany
    • Gruppo Humanitas-Humanitas Research Hospital - Cancer Center · Rozzano, Italy
    • Istituto Oncologico Veneto (IOV) - IRCCS · Padova, Italy
    • Vall d'Hebron Institut d'Oncologia (VHIO) · Barcelona, Spain
    • Hospital Universitario 12 de Octubre (H12O) · Madrid, Spain
    • Sahlgrenska University Hospital · Gothenburg, Sweden
    • Karolinska University Hospital · Solna, Sweden
    • Royal Marsden Hospital · London, United Kingdom
    Show 1 removed
    • Sir Charles Gairdner Hospital · Nedlands, Australia
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Henry Ford Hospital · Detroit, United StatesContact p•••@hfhs.org · •••1606→k•••@hfhs.org · •••7859
    • Rutgers Cancer Institute · New Brunswick, United StatesContact person changed (no phone or email listed)
    • Columbia University Medical Center · New York, United StatesContact person changed (no phone or email listed)
    • University of Texas Southwestern Medical Center · Dallas, United StatesContact person changed (no phone or email listed)
    • Royal North Shore Hospital · Saint Leonards, AustraliaContact person changed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 19, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
    • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United StatesNot yet recruiting→Recruiting
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Mayo Clinic - Arizona · Phoenix, United StatesContact m•••@mayo.edu · •••8227→m•••@mayo.edu · •••0015
    • Mayo Clinic - Florida · Jacksonville, United StatesContact m•••@mayo.edu · •••0856→m•••@mayo.edu · •••0015
    • Mayo Clinic - Rochester · Rochester, United StatesContact m•••@mayo.edu · •••3564→m•••@mayo.edu · •••0015
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact R•••@mskcc.org→y•••@mskcc.org · •••0840Contact •••3051→•••0538
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05303519
Lead sponsor
Nuvation Bio Inc.
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Jun 5, 2023
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Clinical Trials at Nuvation Bio
Contact
ClinicalTrials@nuvationbio.com
332-208-6102

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safusidenib

Start the discussion